Journal
VACCINE
Volume 25, Issue 44, Pages 7656-7663Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.08.042
Keywords
influenza; vaccines; elderly
Categories
Funding
- NCRR NIH HHS [M01-RR-00059, K12 RR023250, M01-RR-16500, K12-RR-023250, M01 RR016500, M01 RR000059] Funding Source: Medline
- NIAID NIH HHS [N01-AI-25461, N01AI30039, N01AI25464, N01AI25461, N01 AI065298-009, N01-AI-25464, N01AI25459, N01 AI030039-009] Funding Source: Medline
Ask authors/readers for more resources
To improve immune responses to influenza vaccine, a trivalent inactivated vaccine containing 60 mu g of the HA of each component (A/H3N2, A/H1N1, B) was compared to a licensed vaccine containing 15 mu g of the HA of each. More local and systemic reactions were reported by subjects given the high dosage but only local pain and myalgias were significantly increased. The high dosage vaccine induced a higher frequency of serum antibody increases (>= 4-fold) in both hemagglutination-inhibiting (HAI) and neutralization tests for all three vaccine viruses in the total group as well as subjects vaccinated and those not vaccinated the previous year. Mean titers of antibody attained, the magnitude of antibody increases and the frequencies of persons with final HAI antibody titers >= 1:32, >= 1:64, and >= 1: 128 were all greater for the high dosage group in both serologic tests, for all groups, and for all vaccine viruses. These increased immune responses should provide increased protection against influenza in the elderly. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available